Dapagliflozin improves diabetic cardiomyopathy by suppressing the STAT3-YY1 signaling axis in cardiac fibroblasts.
DAPA reduces cardiac fibrosis and DCM. This may, at least in part, be attributable to the repression of the STAT3-YY1 signaling axis-mediated CF proliferation and activation, independent of SGLT2 inhibition.
Authors
- Zuo‐Ying Hu (ORCID: https://orcid.org/0000-0001-5324-7179)
- Xin Li (ORCID: https://orcid.org/0000-0001-6432-3966)
- Hao Xie
- Xingyi Shen
Institutions
- Suzhou Municipal Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-01-01
- DOI
- https://doi.org/10.22038/ijbms.2025.87173.18843
- Primary Topic
- Cardiac Fibrosis and Remodeling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China